{"id":5489,"date":"2019-10-07T09:30:31","date_gmt":"2019-10-07T09:30:31","guid":{"rendered":"http:\/\/imas12.es\/en\/?p=5489"},"modified":"2019-10-07T09:30:31","modified_gmt":"2019-10-07T09:30:31","slug":"nueva-inmunoquimioterapia-para-cancer-de-pulmon-agresivo","status":"publish","type":"post","link":"https:\/\/imas12.es\/en\/nueva-inmunoquimioterapia-para-cancer-de-pulmon-agresivo\/","title":{"rendered":"Nueva inmunoquimioterapia para c\u00e1ncer de pulm\u00f3n agresivo"},"content":{"rendered":"<p>The Lancet publica el estudio Caspian, ensayo cl\u00ednico aleatorizado en fase III, coordinado por la Unidad Mixta de C\u00e1ncer de Pulm\u00f3n del Servicio de Oncolog\u00eda M\u00e9dica del <strong><u>Hospital Universitario 12 de Octubre<\/u><\/strong> y el Centro Nacional de Investigaciones Oncol\u00f3gicas (CNIO), que demuestra que una nueva combinaci\u00f3n de quimioterapia e inmunoterapia con durvalumab incrementa la supervivencia en c\u00e1ncer de pulm\u00f3n microc\u00edtico con enfermedad extendida.<\/p>\n<p>En este ensayo cl\u00ednico multic\u00e9ntrico intenacional han participado 209 instituciones de 23 paises y han sido reclutado 573 pacientes con c\u00e1ncer de pulm\u00f3n microc\u00edtico avanzado.<\/p>\n<p>Fuente: <strong>Diario M\u00e9dico<\/strong><\/p>\n<p><a href=\"https:\/\/www.diariomedico.com\/especialidades\/oncologia\/nueva-inmunoquimioterapia-para-cancer-de-pulmon-agresivo.html\" target=\"_blank\" rel=\"noopener\">M\u00e1s Informaci\u00f3n<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Lancet publica el estudio Caspian, ensayo cl\u00ednico aleatorizado en fase III, coordinado por la Unidad Mixta de C\u00e1ncer de Pulm\u00f3n del Servicio de Oncolog\u00eda M\u00e9dica del Hospital Universitario 12 de Octubre y el Centro Nacional de Investigaciones Oncol\u00f3gicas (CNIO),&#8230;<\/p>\n","protected":false},"author":8,"featured_media":5490,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-5489","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sin-categoria"],"_links":{"self":[{"href":"https:\/\/imas12.es\/en\/wp-json\/wp\/v2\/posts\/5489","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/imas12.es\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/imas12.es\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/imas12.es\/en\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/imas12.es\/en\/wp-json\/wp\/v2\/comments?post=5489"}],"version-history":[{"count":1,"href":"https:\/\/imas12.es\/en\/wp-json\/wp\/v2\/posts\/5489\/revisions"}],"predecessor-version":[{"id":5491,"href":"https:\/\/imas12.es\/en\/wp-json\/wp\/v2\/posts\/5489\/revisions\/5491"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/imas12.es\/en\/wp-json\/wp\/v2\/media\/5490"}],"wp:attachment":[{"href":"https:\/\/imas12.es\/en\/wp-json\/wp\/v2\/media?parent=5489"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/imas12.es\/en\/wp-json\/wp\/v2\/categories?post=5489"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/imas12.es\/en\/wp-json\/wp\/v2\/tags?post=5489"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}